Aromatase inhibitors and mammographic breast density in postmenopausal women receiving hormone therapy
- 1 September 2008
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Menopause
- Vol. 15 (5), 875-884
- https://doi.org/10.1097/gme.0b013e31816956c3
Abstract
One of the main concerns regarding long-term use of hormone therapy (HT) in symptomatic menopausal women is the perceived increased risk of breast cancer. A method to reduce breast cancer risk in this population of women is urgently needed. We hypothesized that adding aromatase inhibitors (AIs) to HT would reduce local breast estrogen exposure and breast cancer risk without altering the beneficial systemic effects of HT on menopausal symptoms or bone density. The aim of this study was to investigate the effect of AIs and HT on mammographic breast density (MBD) as a surrogate marker of breast cancer risk in postmenopausal women receiving low-dose HT. This was a retrospective cohort study conducted at private clinics affiliated with a university hospital. One group of postmenopausal women (n = 28) received low-dose HT daily plus letrozole 2.5 mg three times weekly. Postmenopausal women receiving HT alone (n = 28) served as controls. MBD, the primary outcome, was measured using quantitative image analysis software as well as by visual analysis by a radiologist. Hypoestrogenic effects, adverse reactions, and bone mineral densities were secondary outcome measures. The mammograms of 18 women in the study group and 22 women in the control group were suitable for comparison. A statistically significant reduction in MBD occurred in the women who received HT plus an AI, whereas no significant change was observed in the women receiving HT alone. There was no significant increase in hypoestrogenic symptoms during the use of AIs, and bone mineral densities were not significantly reduced. Adding an AI to HT may lower MBD in postmenopausal women. AIs could be good candidates for primary chemoprevention of breast cancer in postmenopausal women using HT.Keywords
This publication has 62 references indexed in Scilit:
- Estrogen Therapy and Coronary-Artery CalcificationNew England Journal of Medicine, 2007
- Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17Journal of Clinical Oncology, 2007
- Mammographic Density and the Risk and Detection of Breast CancerNew England Journal of Medicine, 2007
- Reduction in proliferation with six months of letrozole in women on hormone replacement therapyBreast Cancer Research and Treatment, 2007
- SERMs in chemoprevention of breast cancerEuropean Journal Of Cancer, 2005
- Estrogen-Plus-Progestin Use and Mammographic Density in Postmenopausal Women: Women's Health Initiative Randomized TrialJNCI Journal of the National Cancer Institute, 2005
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Dual role of oestrogens as hormones and pro-carcinogens: tumour initiation by metabolic activation of oestrogensEuropean Journal Of Cancer Prevention, 1997
- ON THE TREATMENT OF INOPERABLE CASES OF CARCINOMA OF THE MAMMA: SUGGESTIONS FOR A NEW METHOD OF TREATMENT, WITH ILLUSTRATIVE CASES.1The Lancet, 1896